An Analysis of NICE’s ‘Restricted’ (or ‘Optimized’) Decisions
Phill O’Neill and
Nancy Devlin (nancy.devlin@unimelb.edu.au)
PharmacoEconomics, 2010, vol. 28, issue 11, 987-993
Abstract:
Background: A common way of describing UK National Institute for Health and Clinical Excellence (NICE) decisions is to distinguish between cases where NICE recommended use of a healthcare technology by all relevant patients (‘yes’); those where it did not recommend use (‘no’); and those where its decisions are a mixture of ‘yes’ to some patient subgroups, and ‘no’ to others. Over half of NICE’s decisions are of this mixed type, which involve restricting (or‘optimizing’) patient use in some way. Objective: To report an attempt to develop a robust and defensible means of measuring and describing the degree of patient access in mixed NICE decisions. Methods: A list of mixed decisions made from 2006 to the end of 2009 was identified using HTAinSite™. The following calculation was used: M= (p/P) × 100, where M is a measure of the level of patient access (0=no access, 100=full access), P is the set of patients considered in the guidance as Potential candidates for treatment (given the licensed use and the scope of NICE’s appraisal), and p is a subset of those patients, for whom NICE did recommend treatment.Mcan be estimated either for a specific product or for a group of technologies (Multiple Technology Appraisals). Both productspecific and overall M were estimated, using estimates of p obtained from NICE costing templates. These data are subject to some important limitations, so the results should be regarded as illustrative. Results: Of the 69 medicines that have received a mixed decision since January 2006, 34 included details that allowed the estimation of M. Of these 34 decisions, 24 (71%) had a product-specific M ≤50, 16 (47%) M ≤25 and 11 (32%) M ≤10. That is, in just under three-quarters of the mixed decisions for which P and p were available, NICE recommended use for less than half of patients for whom the medicine is licensed, and in nearly one-third of these sorts of decisions, NICE recommended use in ≤10% of potential patients. The estimates of M for groups of technologies provide a slightly different picture: for example, grouped M was ≤10 in >20% of decisions. Conclusions: The measure of patient access, M, proposed here has the potential to provide a more informative way of reporting all NICE decisions, particularly ‘restricted’ (or ‘optimized’) decisions. Copyright Adis Data Information BV 2010
Date: 2010
References: Add references at CitEc
Citations: View citations in EconPapers (2)
Downloads: (external link)
http://hdl.handle.net/10.2165/11536970-000000000-00000 (text/html)
Access to full text is restricted to subscribers.
Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
HTML/Text
Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:28:y:2010:i:11:p:987-993
Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273
DOI: 10.2165/11536970-000000000-00000
Access Statistics for this article
PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell
More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla (sonal.shukla@springer.com) and Springer Nature Abstracting and Indexing (indexing@springernature.com).